Filing Flows › X4 Pharmaceuticals (XFOR) › Guidance & outlook
X4 Pharmaceuticals (XFOR) guidance and outlook
X4 Pharmaceuticals' 10-Q filed Nov 4, 2026 makes 5 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 4, 2026
- We expect to complete enrollment in the 4WARD trial by the end of 2026.
- Based on our cash, cash equivalents and marketable securities on hand as of November 4, 2026 and our current operating plan, we believe that our cash, cash equivalents and marketable securities will allow us to fund our operations and debt obligations for at least the next 12 months.
- We expect to continue to incur operating losses as we advance our lead drug candidate through the 4WARD trial.
- Until we reach profitability, we will need to raise additional capital, which cannot be assured, to fund our operations and meet our financial obligations beyond this period.
- • the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies for our product candidates than those that we currently expect;
X4 Pharmaceuticals' latest quarter
X4 Pharmaceuticals, Q3 2026: revenue $2.8M (+75% year over year), operating margin -714.0%, net loss $20.2M, operating cash flow −$20.2M. The chart follows the revenue to costs, profit and cash.
Questions
What does X4 Pharmaceuticals expect?
We expect to complete enrollment in the 4WARD trial by the end of 2026. Based on our cash, cash equivalents and marketable securities on hand as of November 4, 2026 and our current operating plan, we believe that our cash, cash equivalents and marketable securities will allow us to fund our operations and debt obligations for at least the next 12 months. We expect to continue to incur operating losses as we advance our lead drug candidate through the 4WARD trial.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.